NCT07115446View on ClinicalTrials.gov

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Prostate Cancer
Interventions
DRUG

HS-20093

Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

DRUG

HRS-5041

HRS-5041 was given oral administration, QD, at a 21-day cycle.

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY